<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1.5pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of<BR>
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>March 8, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>WaferGen
Bio-systems, Inc.<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-size: 10pt; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt; font-weight: bold; text-align: center">333-136424</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt; font-weight: bold; text-align: center"><B>90-0416683</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt; font-weight: bold; text-align: center"><B>7400 Paseo Padre Parkway<BR>
Fremont, CA</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">94555</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(510) 651-4450</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I> </I>General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1.5pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 5.02.</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Appointment of Chief Executive Officer and Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of March 8, 2012, the board of directors of WaferGen
Bio-systems, Inc. (the &ldquo;Company&rdquo;) appointed Ivan Trifunovich, Ph.D., as President, Chief Executive Officer and director
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dr. Trifunovich, age 48, currently
serves as President, Chief Executive Officer and Chairman of the Board of Helicos BioSciences Corporation, where he has been employed
since October 2010. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Since August 2008, Dr.&nbsp;Trifunovich has
served as a strategic consultant to global companies in the life sciences industry. Previously, Dr.&nbsp;Trifunovich served as
the Senior Vice President of Third Wave Technologies,&nbsp;Inc., a molecular diagnostics company, from December 2001 through August
2008. Prior to joining Third Wave Technologies,&nbsp;Inc., Dr.&nbsp;Trifunovich held successive positions as Vice President of
e-Business and Vice President of Research Strategy and Operations at Pharmacia Corp. Prior to joining Pharmacia, Dr.&nbsp;Trifunovich
was a Director of New Product Marketing at Johnson&nbsp;&amp; Johnson,&nbsp;Inc. He began his career at Bristol-Myers Squibb,&nbsp;Inc.
as a bench scientist, where he held several positions of increasing responsibility. Dr.&nbsp;Trifunovich received his Ph.D. in
organic chemistry at UCLA and an M.B.A. at the University of Pennsylvania's Wharton School of Business. The Company believes Dr.
Trifunovich's qualifications to serve on the board of directors include his extensive executive knowledge and experience in scientific
and business management in the life sciences and molecular diagnostics industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with Dr. Trifunovich&rsquo;s appointment, the
Company and Dr. Trifunovich entered into an executive employment agreement, effective March 8, 2012. Pursuant to the employment
agreement, Dr. Trifunovich will be permitted to continue to serve as President, Chief Executive Officer and Chairman of the Board
of Helicos BioSciences Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the employment agreement, Dr. Trifunovich will receive
an annual base salary of $360,000 per year, and he is eligible to earn an annual performance bonus of up to 50% of his then current
base salary in accordance with an annual incentive plan to be established by the Company&rsquo;s compensation committee or board
of directors. In addition, under the employment agreement, Dr. Trifunovich was granted an initial option grant of 3,000,000 shares
of the Company&rsquo;s common stock with an exercise price equal to $0.14 per share, with one-third of the shares subject to the
option vesting on the first anniversary of Dr. Trifunovich&rsquo;s employment with the Company and the remaining shares vesting
in eight equal quarterly installments over the two years following the first anniversary of the grant date. Dr. Trifunovich is
entitled to additional annual option awards at the beginning of each year as necessary to bring his fully-diluted equity interest
in the Company to 5% at the time of each such grant pursuant to the terms of his employment agreement. All of Dr. Trifunovich&rsquo;s
unvested options granted under his employment agreement will accelerate in the event of a change of control or if his employment
is terminated (except in the case of his resignation without good reason or his termination by the Company for cause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, in the event Dr. Trifunovich is terminated without
cause or resigns for good reason, he is entitled to 24 months of his then-current base salary, of which one-half of such amount
shall be paid in a single lump-sum amount, less applicable withholdings, and the remaining one-half of such amount shall be paid
in the form of salary continuation on the Company&rsquo;s regular payroll schedule, less applicable withholdings, over 18 months.
In addition, if he is terminated without cause or resigns for good reason within 3 months prior to or 12 months following a change
of control of the Company, he is also entitled to receive an additional supplemental severance payment equal to the product of
(ii) 50% of his then-current base salary, multiplied by (ii) two, which supplemental severance payment amount shall be paid in
a single lump-sum amount, less applicable withholdings. Dr. Trifunovich&rsquo;s entitlement to such severance amounts are subject
to his execution of a release of claims in favor of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Trifunovich is eligible to participate in a long-term
incentive plan established by the Company under which he is entitled to receive a cash payment in connection with a change in
control of the Company. Under such plan, in the event of a change in control of the Company, Dr. Trifunovich will be entitled
to a cash payment u<FONT STYLE="font-size: 10pt; font-weight: normal">pon a change of control based on the aggregate equity
transaction value in such change of control transaction, as follows: </FONT>(a) for a transaction with an aggregate equity
transaction value of more than $50 million, and up to $75 million, he will be entitled to receive a cash payment equal to 1%
of the aggregate equity transaction value; (b) for the portion, if any, of the aggregate equity transaction value in excess
of $75 million and up to $100 million, he will be entitled to receive a cash payment equal to 2% of such portion of the
aggregate equity transaction value; (c) for the portion, if any, of the aggregate equity transaction value in excess of $100
million and up to $150 million, he will  be entitled to receive a cash payment equal to 3% of such portion of the aggregate
equity transaction value; and (d) for the portion, if any, of the aggregate equity transaction value in excess of $150
million, he  will be entitled to receive a cash payment equal to 5% of such portion of the aggregate equity transaction
value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has also agreed that Dr. Trifunovich will be entitled
to payment i<FONT STYLE="font-size: 10pt; font-weight: normal">n the event </FONT>that a distribution is made of any of the assets
(including cash) of the Company to holders of any class of capital stock by reason of their ownership thereof. In such case, Dr.
Trifunovich will have the right to receive a payment from the Company in connection with each such distribution equal to the amount,
if any, by which (i) 5% of the total distribution amount exceeds (ii) the amount paid to him in such distribution with respect
to compensatory equity interests then held by him less the exercise or other purchase price paid or payable by him for such equity
interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Trifunovich will be entitled to tax gross up payments in
the event any payments due to him under the employment agreement would be subject to the excise tax imposed by Internal Revenue
Code Section 4999. Dr. Trifunovich also has signed and agreed to be bound by the terms of the Company&rsquo;s proprietary information
and inventions assignment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no family relationship between Dr. Trifunovich and
any director or executive officer and, outside of his employment relationship, he is not a party to any current or proposed transaction
with the Company for which disclosure is required under Item 404(a) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing summary of the terms of Dr. Trifunovich&rsquo;s
employment agreement does not purport to be complete and is qualified in its entirety by the employment agreement attached hereto
as Exhibit 10.1, which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Office of the President</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of March 8, 2012, in connection with Dr. Trifunovich&rsquo;s
appointment as President and Chief Executive Officer, Mona Chadha and Donald Huffman no longer held the duties of the Office of
the President. Ms. Chadha will continue to hold her positions as Chief Operating Officer, Executive Vice President, Marketing and
Business Development and Secretary of the Company, and Mr. Huffman will continue to hold his position as Chief Financial Officer
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 17%; border-bottom: black 1.5pt solid; padding: 0pt; font-size: 10pt">Exhibit&nbsp;No.</TD>
    <TD STYLE="width: 83%; border-bottom: black 1.5pt solid; padding: 0pt; font-size: 10pt">Exhibit Description</TD></TR>
<TR>
    <TD STYLE="padding: 0pt; font-size: 10pt; text-align: left; vertical-align: top">10.1</TD>
    <TD STYLE="padding: 0pt; font-size: 10pt">Executive Employment Agreement, dated as of March 8, 2012, by and between Ivan Trifunovich and WaferGen Bio-systems, Inc.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0"><B>WaferGen Bio-systems, Inc.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0"></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 52%; padding-right: 0.8pt; font-size: 10pt">Date: March 9, 2012</TD>
    <TD STYLE="width: 5%; vertical-align: top; padding-right: 0.8pt; font-size: 10pt">By:</TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid; padding-right: 1.8pt; font-size: 10pt">/s/ Alnoor Shivji</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.8pt; font-size: 10pt">Alnoor Shivji</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chairman of the Board of Directors</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0; text-align: right"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v305355_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 25284}]
{"company-data": {"conformed-name": "WaferGen Bio-systems, Inc.", "cik": "0001368993", "assigned-sic": "3826", "irs-number": "900416683", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53252", "film-number": "12681639"}, "business-address": {"street1": "7400 PASEO PADRE PARKWAY", "city": "FREMONT", "state": "CA", "zip": "94555", "phone": "(510) 651-4450"}, "mail-address": {"street1": "7400 PASEO PADRE PARKWAY", "city": "FREMONT", "state": "CA", "zip": "94555"}, "former-company": {"former-conformed-name": "La Burbuja Cafe, Inc.", "date-changed": "20060714"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 8, 2012
WaferGen
Bio-systems, Inc.
(Exact name of registrant as specified in its charter)
Nevada
333-136424
90-0416683
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
7400 Paseo Padre Parkway
Fremont, CA
94555
(Address of principal executive offices)
Zip Code)
Registrant's telephone number, including
area code:
(510) 651-4450
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction
A.2. below):
£
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Executive Officer and Director
Effective as of March 8, 2012, the board of directors of WaferGen
Bio-systems, Inc. (the "Company") appointed Ivan Trifunovich, Ph.D., as President, Chief Executive Officer and director
of the Company.
Dr. Trifunovich, age 48, currently
serves as President, Chief Executive Officer and Chairman of the Board of Helicos BioSciences Corporation, where he has been employed
since October 2010.
Since August 2008, Dr. Trifunovich has
served as a strategic consultant to global companies in the life sciences industry. Previously, Dr. Trifunovich served as
the Senior Vice President of Third Wave Technologies, Inc., a molecular diagnostics company, from December 2001 through August
2008. Prior to joining Third Wave Technologies, Inc., Dr. Trifunovich held successive positions as Vice President of
e-Business and Vice President of Research Strategy and Operations at Pharmacia Corp. Prior to joining Pharmacia, Dr. Trifunovich
was a Director of New Product Marketing at Johnson & Johnson, Inc. He began his career at Bristol-Myers Squibb, Inc.
as a bench scientist, where he held several positions of increasing responsibility. Dr. Trifunovich received his Ph.D. in
organic chemistry at UCLA and an M.B.A. at the University of Pennsylvania's Wharton School of Business. The Company believes Dr.
Trifunovich's qualifications to serve on the board of directors include his extensive executive knowledge and experience in scientific
and business management in the life sciences and molecular diagnostics industries.
In connection with Dr. Trifunovich's appointment, the
Company and Dr. Trifunovich entered into an executive employment agreement, effective March 8, 2012. Pursuant to the employment
agreement, Dr. Trifunovich will be permitted to continue to serve as President, Chief Executive Officer and Chairman of the Board
of Helicos BioSciences Corporation.
Under the employment agreement, Dr. Trifunovich will receive
an annual base salary of $360,000 per year, and he is eligible to earn an annual performance bonus of up to 50% of his then current
base salary in accordance with an annual incentive plan to be established by the Company's compensation committee or board
of directors. In addition, under the employment agreement, Dr. Trifunovich was granted an initial option grant of 3,000,000 shares
of the Company's common stock with an exercise price equal to $0.14 per share, with one-third of the shares subject to the
option vesting on the first anniversary of Dr. Trifunovich's employment with the Company and the remaining shares vesting
in eight equal quarterly installments over the two years following the first anniversary of the grant date. Dr. Trifunovich is
entitled to additional annual option awards at the beginning of each year as necessary to bring his fully-diluted equity interest
in the Company to 5% at the time of each such grant pursuant to the terms of his employment agreement. All of Dr. Trifunovich's
unvested options granted under his employment agreement will accelerate in the event of a change of control or if his employment
is terminated (except in the case of his resignation without good reason or his termination by the Company for cause).
In addition, in the event Dr. Trifunovich is terminated without
cause or resigns for good reason, he is entitled to 24 months of his then-current base salary, of which one-half of such amount
shall be paid in a single lump-sum amount, less applicable withholdings, and the remaining one-half of such amount shall be paid
in the form of salary continuation on the Company's regular payroll schedule, less applicable withholdings, over 18 months.
In addition, if he is terminated without cause or resigns for good reason within 3 months prior to or 12 months following a change
of control of the Company, he is also entitled to receive an additional supplemental severance payment equal to the product of
(ii) 50% of his then-current base salary, multiplied by (ii) two, which supplemental severance payment amount shall be paid in
a single lump-sum amount, less applicable withholdings. Dr. Trifunovich's entitlement to such severance amounts are subject
to his execution of a release of claims in favor of the Company.
Dr. Trifunovich is eligible to participate in a long-term
incentive plan established by the Company under which he is entitled to receive a cash payment in connection with a change in
control of the Company. Under such plan, in the event of a change in control of the Company, Dr. Trifunovich will be entitled
to a cash payment u
pon a change of control based on the aggregate equity
transaction value in such change of control transaction, as follows:
(a) for a transaction with an aggregate equity
transaction value of more than $50 million, and up to $75 million, he will be entitled to receive a cash payment equal to 1%
of the aggregate equity transaction value; (b) for the portion, if any, of the aggregate equity transaction value in excess
of $75 million and up to $100 million, he will be entitled to receive a cash payment equal to 2% of such portion of the
aggregate equity transaction value; (c) for the portion, if any, of the aggregate equity transaction value in excess of $100
million and up to $150 million, he will  be entitled to receive a cash payment equal to 3% of such portion of the aggregate
equity transaction value; and (d) for the portion, if any, of the aggregate equity transaction value in excess of $150
million, he  will be entitled to receive a cash payment equal to 5% of such portion of the aggregate equity transaction
value.
The Company has also agreed that Dr. Trifunovich will be entitled
to payment i
n the event
that a distribution is made of any of the assets
(including cash) of the Company to holders of any class of capital stock by reason of their ownership thereof. In such case, Dr.
Trifunovich will have the right to receive a payment from the Company in connection with each such distribution equal to the amount,
if any, by which (i) 5% of the total distribution amount exceeds (ii) the amount paid to him in such distribution with respect
to compensatory equity interests then held by him less the exercise or other purchase price paid or payable by him for such equity
interests.
Dr. Trifunovich will be entitled to tax gross up payments in
the event any payments due to him under the employment agreement would be subject to the excise tax imposed by Internal Revenue
Code Section 4999. Dr. Trifunovich also has signed and agreed to be bound by the terms of the Company's proprietary information
and inventions assignment agreement.
There is no family relationship between Dr. Trifunovich and
any director or executive officer and, outside of his employment relationship, he is not a party to any current or proposed transaction
with the Company for which disclosure is required under Item 404(a) of Regulation S-K.
The foregoing summary of the terms of Dr. Trifunovich's
employment agreement does not purport to be complete and is qualified in its entirety by the employment agreement attached hereto
as Exhibit 10.1, which is incorporated herein by reference.
Office of the President
Effective as of March 8, 2012, in connection with Dr. Trifunovich's
appointment as President and Chief Executive Officer, Mona Chadha and Donald Huffman no longer held the duties of the Office of
the President. Ms. Chadha will continue to hold her positions as Chief Operating Officer, Executive Vice President, Marketing and
Business Development and Secretary of the Company, and Mr. Huffman will continue to hold his position as Chief Financial Officer
of the Company.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits
Exhibit No.
Exhibit Description
10.1
Executive Employment Agreement, dated as of March 8, 2012, by and between Ivan Trifunovich and WaferGen Bio-systems, Inc.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
WaferGen Bio-systems, Inc.
Date: March 9, 2012
By:
/s/ Alnoor Shivji
Alnoor Shivji
Chairman of the Board of Directors